– USA, CA – Lineage Cell Therapeutics, Inc. (NYSE American / TASE: LCTX) today announced the appointment of Michael Mulroy as the Chairman of the Board of Directors effective as of April 27, 2024, replacing Al Kingsley who passed away.
About Michael Mulroy
His background includes experience as a biotech and biopharma corporate executive and as a corporate attorney and investment banker. He has served as a member of the Board of Directors since 2014 and serves as Chair of the Compensation Committee and as a member of the Audit Committee and the Financial Strategy Committee. Michael Mulroy brings extensive expertise across several operational and functional areas, including corporate finance and development, and clinical and strategic operations. He previously served as CEO and a member of the board of directors of Asterias Biotherapeutics, Inc. Before joining Asterias, Mr. Mulroy served as a Senior Advisor to CamberView Partners, LLC (now part of PJT Partners Inc.), which assists companies in connection with investor engagement and complex corporate governance issues. Before its sale in 2014, Michael Mulroy served as EVP, Strategic Affairs, and General Counsel of Questcor Pharmaceuticals, Inc. (QCOR), where he also previously served as CFO.
Michael Mulroy earned his J.D. degree from the University of California, Los Angeles, and his B.A. degree in economics from the University of Chicago.
About Lineage Cell Therapeutics, Inc.
Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel or “off-the-shelf,” cell therapies to address unmet medical needs. Lineage’s programs are based on its proprietary cell-based technology platform and associated development and manufacturing capabilities. From this platform, Lineage designs, develops, manufactures, and tests specialized human cells with anatomical and physiological functions similar or identical to cells found naturally in the human body. These cells are created by applying directed differentiation protocols to established, well-characterized, and self-renewing pluripotent cell lines. These protocols generate cells with characteristics associated with specific and desired developmental lineages. Cells derived from such lineages are transplanted into patients to replace or support cells that are absent or dysfunctional due to degenerative disease, aging, or traumatic injury, and to restore or augment the patient’s functional activity. Lineage’s neuroscience-focused pipeline currently includes
- (i) OpRegen, a retinal pigment epithelial cell therapy in Phase 2a development under a worldwide collaboration with Roche and Genentech, a member of the Roche Group, for the treatment of geographic atrophy secondary to age-related macular degeneration;
- (ii) OPC1, an oligodendrocyte progenitor cell therapy in Phase 1/2a development for the treatment of spinal cord injuries;
- (iii) ANP1, an auditory neuronal progenitor cell therapy for the potential treatment of auditory neuropathy;
- (iv) PNC1, a photoreceptor neural cell therapy for the potential treatment of vision loss due to photoreceptor dysfunction or damage;
- (v) RND1, a novel hypoimmune induced pluripotent stem cell l
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
